Cerenis Therapeutics Completes Phase I Clinical Trial Of CER-002 For Treatment Of Cardiovascular Disease
Cerenis Therapeutics SA (Cerenis), a privately held pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, announced that it has completed a Phase I clinical trial for CER-002, one of the company's lead product candidates.
VIA Pharmaceuticals Completes Enrollment In Phase 2 Acute Coronary Syndrome ACS Trial
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced that it has completed patient enrollment in its acute coronary syndrome (ACS) study. The ACS study is one of three Phase 2 trials investigating VIA-2291, the company's lead product candidate in cardiovascular disease.
IDM Pharma Announces Updated Data From Mifamurtide L-MTP-PE Compassionate Access Program
IDM Pharma, Inc. (the Company) (Nasdaq: IDMI) announced the presentation of updated data from a compassionate access program evaluating mifamurtide (L-MTP-PE) in patients with lung metastases as a result of the progression of osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.
Manufacturer Removes Remaining Stocks Of Trasylol
Background: On Nov. 5, 2007, the U.S. Food and Drug Administration announced that Bayer Pharmaceuticals Corp. agreed to an FDA-requested marketing suspension of Trasylol, a drug used to control bleeding during heart surgery. At that time, preliminary results from a Canadian study suggested an increased risk for death compared to two other drugs used to control bleeding.
Novel Enzyme Inhibitor Paves Way For New Cancer Drug
Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.
Poniard To Present Clinical Data From Picoplatin Trials In Multiple Tumor Types At American Society Of Clinical Oncology 2008 Annual Meeting
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago.
International Diabetes Federation Grant Supports Diabetes Screening And Prevention Program In Vietnam
The International Diabetes Federation (IDF) BRIDGES translational research grant program will fund a pilot study in Vietnam to increase opportunities for screenings for people at high-risk for getting type 2 diabetes and promote a program designed to motivate people to develop a healthy lifestyle.
Breast Cancer Spread And Poorer Survival Linked To Vitamin D
Research from Canada suggests that women with breast cancer who were low in Vitamin D at the time of their diagnosis had a higher risk of the cancer spreading and poorer survival rates compared with women who had adequate levels of Vitamin D.
Average 2008 Employee Out-of-Pocket Costs For Family Health Care To Increase 10.5 , According To Milliman Index
The cost of health care for the average U.S. family with employer-sponsored health coverage will increase 7.6% this year, due in part to rising prescription drug prices, according to a Milliman study released on Wednesday, Dow Jones reports.
Racial Disparities In Diabetes Control Not Solely Linked To Lower Treatment Adherence Among Blacks, Study Finds
Lower diabetes treatment adherence among blacks does not fully explain racial disparities in diabetes control, according to a study published in the journal Diabetes Care, Reuters Health reports. Blacks with type 2 diabetes tend to have more problems controlling their blood sugar than whites and also are at a higher risk of developing complications from diabetes, according to Reuters Health.